Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

NCT04276493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

BIOLOGICAL: Zanidatamab
DRUG: Docetaxel
BIOLOGICAL: Tislelizumab
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

BeiGene